title: Effect of recombinant human erythropoietin on vascular access.
abstract: The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.
authors.affiliation: Kraftsow Division of Nephrology, Albert Einstein Medical Center, Philadelphia 19141.
authors.forename: G R
authors.initials: GR
authors.lastname: Dy
authors.forename: E J
authors.initials: EJ
authors.lastname: Bloom
authors.forename: G K
authors.initials: GK
authors.lastname: Ijelu
authors.forename: G W
authors.initials: GW
authors.lastname: Merritts
authors.forename: M S
authors.initials: MS
authors.lastname: Kramer
authors.forename: R M
authors.initials: RM
authors.lastname: Raja
mesh_terms: D000368:Aged; D001166:Arteriovenous Shunt, Surgical; D001807:Blood Vessel Prosthesis; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000139:chemically induced; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D011138:Polytetrafluoroethylene